Article Text

Download PDFPDF

  1. M. Jordhani1,
  2. D. Ruci1,
  3. V. Ruci2
  1. 1UHC Mother Teresa, Tirana, Albania, Internal Medicine, Tirana, Albania
  2. 2University Trauma Hospital Tirana, Orthopaedics, Tirana, Albania


Background: Because of the inflammation boosting cytokines, Coronavirus disease 2019 (COVID-19) has demonstrated thrombotic consequences that have increased its morbidity and mortality. There is evidence that mechanisms that contribute in thrombosis in COVID-19 patients are similar to those in anti-phospholipid syndrome (aPS). In fact, there is a possibility that anti-phospholipid autoantibodies (aPLs) might impulse thrombosis in patients with COVID-19, as literature suggests2.

Objectives: The aim of our study was to evaluate the anti-phospholipid autoantibody titre in patients with COVID-19 during and after the infection.

Methods: This is an observational study which included 71 patients with a recent COVID-19 up to 4 weeks after. Every patient was completed with aPL titre about IgG and IgM anti-cardiolipine (ACA) and lupus anticoagulant (LAC) autoantibodies. According to titre results, the patients were divided into groups in order to better show the immunologic results.

Results: After gathering and analysing the data, it was estimated that 21 patients (29.6%) were positive for at least one type of aPL antibody: 12 patients were found positive for lupus anticoagulant autoantibodies (57.1%), 6 patients were double positive for LAC and ACA (28.6%), and 3 patients were positive for anti-cardiolipin antibodies (14.3%). Seven patients were IgM positive for any aPL (33.3%), 6 patients were found to have positive IgM and IgG (28.6%) and 8 patients had only IgG antibodies (38.1%).

Conclusion: From this study it was observed that a significant proportion of patients with recent COVID-19 infection had positive anti-phospholipid antibodies, compared to the general population prevalence. This suggests that the impact of aPLs in COVID-19 might be of great importance. It should be carefully evaluated in order to better understand the mechanisms of thrombotic complications.

References: [1]Wise Jacqui. Covid-19 and thrombosis: what do we know about the risks and treatment? BMJ 2020; 369:m2058

[2]Zuo, Yu, et al. “Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19.” Science translational medicine 12.570 (2020).

Disclosure of Interests: None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.